Federal Register Notice: FDA’s proposed collection of information, “Postmarketing Adverse Drug Experience Reporting — 21 CFR 310.305 and 314.80,” has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. To view this notice, click here.
